Abstract
Over the last few years, the implication of the (pro)renin receptor [(P)RR] in the pathogenesis of end-organ damage has been shown through many different studies. The (P)RR plays a dual role when stimulated by renin or prorenin as it enhances both cell surface production of angiotensin and stimulates angiotensin-independent intracellular signaling cascades. Since Ichiharas group demonstrated activation of prorenin when it was bound to antibodies targeted against a specific region in the renin prosegment, they designed a complementary decapeptide to this region called the handle region to use as a potential (P)RR blocker (PRRB). The effects of systemic administration of the PRRB on the development and progression of different renal, cardiac and ocular pathologies have been observed and have thus proposed the blocker as a potential new treatment for these afflictions. Conversely, the specificity of the PRRB has been questioned as conflicting results have been reported in the literature. A recent study has described a new high affinity binding site for renin and prorenin to the (P)RR called the hinge region. Hence, although there is great promise in the (P)RR potential as a therapeutic target, still much research is required to better identify adequate blockers.
Keywords: (pro)renin receptor, (pro)renin receptor blocker, renin-angiotensin system, renal disease, ocular disease, cardiac pathology, central nervous system, transgenic animals, cAMP, fibrosis
Current Pharmaceutical Design
Title: (Pro)renin Receptor as a New Drug Target
Volume: 17 Issue: 33
Author(s): Basma A.M. Ahmed, Ondrej Seda and Julie L. Lavoie
Affiliation:
Keywords: (pro)renin receptor, (pro)renin receptor blocker, renin-angiotensin system, renal disease, ocular disease, cardiac pathology, central nervous system, transgenic animals, cAMP, fibrosis
Abstract: Over the last few years, the implication of the (pro)renin receptor [(P)RR] in the pathogenesis of end-organ damage has been shown through many different studies. The (P)RR plays a dual role when stimulated by renin or prorenin as it enhances both cell surface production of angiotensin and stimulates angiotensin-independent intracellular signaling cascades. Since Ichiharas group demonstrated activation of prorenin when it was bound to antibodies targeted against a specific region in the renin prosegment, they designed a complementary decapeptide to this region called the handle region to use as a potential (P)RR blocker (PRRB). The effects of systemic administration of the PRRB on the development and progression of different renal, cardiac and ocular pathologies have been observed and have thus proposed the blocker as a potential new treatment for these afflictions. Conversely, the specificity of the PRRB has been questioned as conflicting results have been reported in the literature. A recent study has described a new high affinity binding site for renin and prorenin to the (P)RR called the hinge region. Hence, although there is great promise in the (P)RR potential as a therapeutic target, still much research is required to better identify adequate blockers.
Export Options
About this article
Cite this article as:
A.M. Ahmed Basma, Seda Ondrej and L. Lavoie Julie, (Pro)renin Receptor as a New Drug Target, Current Pharmaceutical Design 2011; 17 (33) . https://dx.doi.org/10.2174/138161211798220963
DOI https://dx.doi.org/10.2174/138161211798220963 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry Peroxisome Proliferator-Activated Receptor γ Agonists as Insulin Sensitizers: From the Discovery to Recent Progress
Current Topics in Medicinal Chemistry Editorial [Herbal Remedies in Pulmonary Medicine: A Word of Caution]
Current Respiratory Medicine Reviews Aqueous Extract of Matricaria pubescens Exhibits Antihypertensive Activity in L-NAME-induced Hypertensive Rats through its Vasorelaxant Effect
Cardiovascular & Hematological Agents in Medicinal Chemistry Meet Our Associate Editor
Current Molecular Medicine Recent Insights into the Role of Prostanoids in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Genetic Polymorphism of LDLR (rs688) is Associated with Primary Intracerebral Hemorrhage
Current Neurovascular Research Mitochondrially Targeted Antioxidants for the Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Editorial : (Thematic issue: Critical Appraisal of Ischemic Stroke Pathophysiology: Road to Cerebral Resuscitation? Part II)
Current Medicinal Chemistry Hypertension, Cognitive Impairment and Dementia: An Epidemiological Perspective
Current Hypertension Reviews Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Current Opinion and Future Trends)
Current Pharmaceutical Design Protective Effects of Heme-Oxygenase Expression in Cyclosporine A - Induced Injury
Current Neurovascular Research Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer
Current Drug Targets Hydrogen Sulfide: From Physiology to Pharmacology
Inflammation & Allergy - Drug Targets (Discontinued) Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews Multiple Pregnancies After ART and How to Minimize their Occurrence
Current Women`s Health Reviews Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Inflammatory Biomarkers in Chronic Kidney Disease: A Review
Recent Patents on Biomarkers In vivo and in silico Investigation of Antidiabetic Activity of Fruit of Withania coagulans Dunal
Current Hypertension Reviews Small-Molecules Targeting Kinases Involved in Pulmonary Hypertension: a Patent Review (2010-2015)
Current Medicinal Chemistry